JGB1741
CAS No. : 1256375-38-8
(Synonyms: ILS-JGB-1741)
| Size | Price | Stock |
|---|---|---|
| 1mg | $68 | In-stock |
| 5mg | $220 | In-stock |
| 10mg | $375 | In-stock |
| 25mg | $750 | In-stock |
| 50mg | $1200 | In-stock |
| 100mg | $1900 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-111329 |
| M.Wt: | 440.56 |
| Formula: | C27H24N2O2S |
| Purity: | >98 % |
| Solubility: | DMSO : 5 mg/mL (ultrasonic) |
JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research[1].
In Vitro: JGB1741 (ILS-JGB-1741; 1-10000 nM; 24 h) inhibits MDA-MB 231 cell proliferation[1].
JGB1741 (0.01-1 μM; 24 h) induces apoptosis of MDA-MB 231 cells[1].
JGB1741 (0.01-1 μM; 24 h) shows a cell cycle arrest at G1 phase with more and more cells entering into sub G0/G1 phase[1].
JGB1741 (0.01-1 μM; 24 h) shows an increase in the global acetylation of H3K9, p53 expression and acetylated p53K382 levels[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- JGB1741
- Cat. No.:
- HY-111329
- Quantity:
Your information is safe with us.